DrugPatentWatch Database Preview

NEURACEQ Drug Profile

« Back to Dashboard

When do Neuraceq patents expire, and when can generic versions of Neuraceq launch?

Neuraceq is a drug marketed by Piramal Imaging and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-five countries.

The generic ingredient in NEURACEQ is florbetaben f-18. Additional details are available on the florbetaben f-18 profile page.

Summary for NEURACEQ

International Patents:	33
US Patents:	1
Applicants:	1
NDAs:	1
Bulk Api Vendors:	1
Clinical Trials:	2
Patent Applications:	8
Drug Prices:	see details
DailyMed Link:	NEURACEQ at DailyMed

Synonyms for NEURACEQ

[18F]BAY 94-9172

18F-BAY94-9172

18F-Florbetaben

4-((1E)-2-(4-(2-(2-(2-((sup 18(f))fluoroethoxy)ethoxy)ethoxy)phenyl)eth-1-en-1-yl)-N-methylaniline

4-[(E)-2-[4-[2-[2-(2-fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-N-methylaniline

4-{(E)-2-[4-(2-{2-[2-((18)F)fluoroethoxy]ethoxy}ethoxy)phenyl]ethenyl}-N-methylaniline

902143-01-5

AV-1

BAY 94-9172

BAY-949172

BAY94-9172

CHEBI:79033

CHEMBL566752

DB09148

DTXSID20238065

Florbetaben

florbetaben ((18)F)

Florbetaben ((sup 18)F)

Florbetaben (18F)

Florbetaben (18F) (JAN/INN)

Florbetaben (18F) [INN]

Florbetaben 18F [INN]

Florbetaben F 18

Florbetaben F-18

Florbetaben F18

Florbetaben f18 [USAN]

GTPL7769

Neuraceq (TN)

SCHEMBL11301755

TLA7312TOI

UNII-TLA7312TOI

US Patents and Regulatory Information for NEURACEQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Piramal Imaging	NEURACEQ	florbetaben f-18	SOLUTION;INTRAVENOUS	204677-001	Mar 19, 2014		RX	Yes	Yes			Y	Y
Piramal Imaging	NEURACEQ	florbetaben f-18	SOLUTION;INTRAVENOUS	204677-001	Mar 19, 2014		RX	Yes	Yes

Non-Orange Book US Patents for NEURACEQ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,858,072	Stilbene derivatives and their use for binding and imaging amyloid plaques
8,465,726	Stilbene derivatives and their use for binding and imaging amyloid plaques

International Patents for NEURACEQ

Country	Document Number	Estimated Expiration
South Africa	200705104
Norway	339195
Israel	183946
Mexico	2007007380

Supplementary Protection Certificates for NEURACEQ

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0719	Netherlands		PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906 20140224
4	Finland
00719	Netherlands		PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906 20140220
647	Luxembourg		PRODUCT NAME: FLORBETABEN (18F). FIRST REGISTRATION: 20140224